Compare PTY & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PTY | TMDX |
|---|---|---|
| Founded | 2002 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.9B |
| IPO Year | N/A | 2019 |
| Metric | PTY | TMDX |
|---|---|---|
| Price | $12.88 | $124.15 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $144.25 |
| AVG Volume (30 Days) | 550.4K | ★ 724.8K |
| Earning Date | 01-01-0001 | 10-29-2025 |
| Dividend Yield | ★ 9.65% | N/A |
| EPS Growth | N/A | ★ 170.70 |
| EPS | N/A | ★ 2.54 |
| Revenue | N/A | ★ $566,354,000.00 |
| Revenue This Year | N/A | $38.81 |
| Revenue Next Year | N/A | $20.49 |
| P/E Ratio | ★ N/A | $48.97 |
| Revenue Growth | N/A | ★ 41.20 |
| 52 Week Low | $11.92 | $55.00 |
| 52 Week High | $14.88 | $156.00 |
| Indicator | PTY | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 34.52 | 43.84 |
| Support Level | $12.77 | $120.82 |
| Resistance Level | $12.95 | $133.29 |
| Average True Range (ATR) | 0.08 | 5.52 |
| MACD | 0.01 | -0.91 |
| Stochastic Oscillator | 27.85 | 19.55 |
PIMCO Corporate & Income Opportunity Fds operates as a closed-end management investment company. It seeks to maximize total return through a combination of current income and capital appreciation. The fund invests a majority of the total assets in a combination of corporate debt obligations of varying maturities, other corporate income-producing securities, and income-producing securities of non-corporate issuers, such as U.S. Government securities, municipal securities, and mortgage-backed and other asset-backed securities issued on a public or private basis.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.